PMID: 2123203Sep 1, 1990Paper

Topical Bactroban (mupirocin): efficacy in treating burn wounds infected with methicillin-resistant staphylococci

The Journal of Burn Care & Rehabilitation
L L StrockJ P Heggers

Abstract

Bacterial antimicrobial susceptibility predictors such as the minimal inhibitory concentration (MIC) assay and Nathans Agar Well Diffusion (NAWD) assay provide essential information relevant to the therapeutic approach in burn-wound sepsis. The susceptibilities of 68 gram-positive burn-wound isolates were tested against topical Bactroban (mupirocin) (Beecham Laboratories, Bristol, Tenn.) and compared with other topical antimicrobials such as mafenide acetate, silver sulfadiazine, and bacitracin/neomycin/polymyxin (BNP). Topical susceptibility data were obtained with a modification of NAWD assay. Bactroban's antimicrobial activity was greater than that of mafenide acetate (100% vs 97%), and significantly greater than that of silver sulfadiazine and that of BNP (p less than 0.001). Of the 68 isolates that were susceptible to Bactroban, 51 were predominately methicillin-resistant staphylococci (MRSA). Bactroban showed in vitro activity against 71% of the 85 gram-negative isolates tested. Mafenide acetate showed activity against 89% of these isolates, a significant difference compared with Bactroban (p less than 0.02). In general, no significant difference was found between the activities of Bactroban and silver sulfadiazine agains...Continue Reading

Citations

Dec 25, 2003·Burns : Journal of the International Society for Burn Injuries·Edward E TredgetSarvesh Logsetty
Jan 9, 1999·Burns : Journal of the International Society for Burn Injuries·M Prasanna, C Thomas
Apr 29, 2005·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Robert L Sheridan
Dec 9, 2008·Journal of Burn Care & Research : Official Publication of the American Burn Association·Alice N NeelyRichard J Kagan
Jul 25, 2008·The Journal of Craniofacial Surgery·Priti P PatelSamuel T Rhee
Jun 1, 1995·Antimicrobial Agents and Chemotherapy·S T BoyceI A Holder
Apr 15, 2006·Clinical Microbiology Reviews·Deirdre ChurchRobert Lindsay
Nov 20, 2012·Indian Journal of Plastic Surgery : Official Publication of the Association of Plastic Surgeons of India·Katara GunjanDhananjay Sadashiv Chitnis
Jun 15, 2010·Burns : Journal of the International Society for Burn Injuries·Jessie S GlasserClinton K Murray
Apr 3, 2007·Emergency Medicine Clinics of North America·Paresh R Patel, Michael A Miller
Jun 27, 2012·Veterinary Dermatology·Ralf S MuellerRoss Bond
Oct 1, 1991·Clinics in Dermatology·L Andreassi, L Flori
Oct 1, 1993·Burns : Journal of the International Society for Burn Injuries·M J Vizcaino-AlcaideJ Rey-Calero
Jun 26, 2003·The Surgical Clinics of North America·Gerald T Lionelli, W Thomas Lawrence
May 4, 1999·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·E E UdoS C Sanyal
Apr 26, 2000·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·I A Holder, S T Boyce
Nov 17, 2016·Journal of Biomaterials Science. Polymer Edition·Xinxin ChenCe Wang
Jan 1, 2013·Journal of Functional Biomaterials·Deepen PaulPankaj Vadgama
Jul 12, 2019·Journal of Nanobiotechnology·Wei WangYong-Zhong Du

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.